Adacyte events

When more is needed: Adacolumn®, the synergy of a non-drug treatment (In Spanish)

The goal of treatment in ulcerative colitis (UC) is to induce and maintain remission. The addition of granulocyte and monocyte apheresis (GMA) to conventional therapy may be a promising therapeutic alternative.

June 16, 2022


Palma de Mallorca, Spain

GMA was clearly demonstrated to induce and maintain clinical remission more effectively than conventional therapy alone both for induction and for maintenance. GMA improves the rates of clinical response and clinical remission in these patients and shows an steroid sparing effect and an excellent safety profile. GMA would be particularly important for specific subgroups where the safety profile is of paramount importance

Javier Martín de Carpi (Head of Gastroenterology, Hepatology Gastroenterology, Hepatology and Nutrition, Hospital Sant Joan de Déu, Barcelona).

José Luis Cabriada (Head of Digestive Digestive Service, Hospital Galdakao, Galdakao)

Daniel Ginard (Head of Digestive Service, Hospital Universitario Son Espases, Mallorca).

Gastroenterologists, Paediatric gastroenterologists and physicians and allied health professionals interested in therapeutic apheresis, including both established practitioners and those embarking on a new apheresis service (nephrologists, haematologists, clinical pathologists, blood banks, nurses…etc).


Contact UsFor more information

Contact Us